|
Vascular Endothelial Growth Factor (VEGF) in Uveitis Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Vascular Endothelial Growth Factor (VEGF) in Uveitis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Vascular Endothelial Growth Factor (VEGF) in Uveitis Clinical research trials and Vascular Endothelial Growth Factor (VEGF) in Uveitis medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Vascular Endothelial Growth Factor (VEGF) in Uveitis. Vascular Endothelial Growth Factor (VEGF) in Uveitis Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Vascular Endothelial Growth Factor (VEGF) in Uveitis clinical trial. Test subjects typically obtain the finest healthcare available for their Vascular Endothelial Growth Factor (VEGF) in Uveitis condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vascular Endothelial Growth Factor (VEGF) in Uveitis  Vascular Endothelial Growth Factor (VEGF) in Uveitis
Vascular Endothelial Growth Factor (VEGF) in Uveitis
For Condition: Macular Edema, Cystoid,Uveitis
Status: Completed
Sponsor(s): National Eye Institute (NEI) ,
Synopsis: This study will look for the presence in blood of a substance called vascular endothelial growth factor (VEGF) in patients with uveitis (eye inflammation). It will also look for this substance in eye fluid samples taken from patients with uveitis who are undergoing eye surgery. Some patients with uveitis experience some vision loss during an inflammatory attack because of swelling (edema) in a particular area of the retina called the macula, which is involved in visual acuity. It may be that VEGF is involved in the development of macular edema. Patients with uveitis who participate in this study will have about 10 cc (2 teaspoons) of blood drawn to be examined for VEGF. They will also undergo a procedure called fluorescein angiography to look at the blood vessels of the eye. A dye called sodium fluorescein is injected into the blood stream through a vein. After the dye reaches the blood vessels of the eye, photographs are taken of the retina. In addition, patients with uveitis who are undergoing eye surgery will have a tissue specimen (either aqueous fluid or vitreous gel) collected for examination for the presence of VEGF.
Details: Increased intraocular and systemic levels of the angiogenic factor vascular endothelial growth factor (VEGF) is associated with new vessel growth in the eye, such as diabetic retinopathy. Recent work using immunopathologic techniques have shown that VEGF is upregulated in both experimentally induced uveitis and in uveitic eyes as well, with no evidence of neovascularization. This pilot study will evaluate the level of VEGF in the blood of uveitic patients with and without macular edema. This level will be determined also in the ocular fluid of those patients that are undergoing ocular surgery. These levels will be compared with age and sex matched controls.
Eligibility:
Study Type: Observational, Screening
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: For Uveitis Patients: Evidence on ocular examination in the past or presently of intraocular inflammation, with cells and haze in the vitreous for the intermediate and posterior uveitis patients. In order to demonstrate the presence or absence of macular edema, a fluorescein angiogram will be attempted on all patients. However, if the patient is unable or not willing to undergo the test, then if two observers from the LI can substantiate independently that there is or is not evidence of cystoid edema, the patient may be included.
Total Enrollment: 60
Location and Contact Information:
National Eye Institute (NEI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 980152; 98-EI-0152
Study Start Date: August 26, 1998
Record last reviewed: August 17, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001738
Other Uveitis Studies:
1. The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated with Juvenile Rheumatoid Arthritis
2. Cyclosporin Implant to Treat Uveitis
3. HAT in Eye Complications of Behcet's Disease
4. ANTI-TAC THERAPY FOR UVEITIS
5. Effect of Pregnancy on Uveitis
Related Studies:
Other Uveitis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Vascular Endothelial Growth Factor (VEGF) in Uveitis
|
|
|
|
|
|
|
|
